(Q38588541)

English

Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies

scientific article published on 18 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 September 2017

0 references

Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies (English)

1 reference

Europe PubMed Central

4 September 2017

fatty liver disease

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

author name string

Wenjuan Tang

1

1 reference

Europe PubMed Central

4 September 2017

Qianyue Xu

2

1 reference

Europe PubMed Central

4 September 2017

Ting Hong

3

1 reference

Europe PubMed Central

4 September 2017

Guoyu Tong

4

1 reference

Europe PubMed Central

4 September 2017

Wenhuan Feng

5

1 reference

Europe PubMed Central

4 September 2017

Shanmei Shen

6

1 reference

Europe PubMed Central

4 September 2017

Yan Bi

7

1 reference

Europe PubMed Central

4 September 2017

Dalong Zhu

8

1 reference

Europe PubMed Central

4 September 2017

publication date

18 September 2015

1 reference

Europe PubMed Central

4 September 2017

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

4 September 2017

32

1 reference

Europe PubMed Central

4 September 2017

2

1 reference

Europe PubMed Central

4 September 2017

200-216

1 reference

Europe PubMed Central

4 September 2017

Global estimates of diabetes prevalence for 2013 and projections for 2035.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Inverse association between liver fat content and hepatic glucose uptake in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Estimating the mean and variance from the median, range, and the size of a sample

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Incretin mimetics as a novel therapeutic option for hepatic steatosis

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Metabolic disturbances in non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Dyslipidemia in patients with nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Newly diagnosed diabetes mellitus as a risk factor for serious liver disease

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link?

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

21 January 2018

A position statement on NAFLD/NASH based on the EASL 2009 special conference

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

7 January 2021

based on heuristic

inferred from DOI database lookup

Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2713

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DMRR.2713

1 reference

Europe PubMed Central

4 September 2017

release_yz66ojshv5htbfcysktcw3dq5e

1 reference

https://api.fatcat.wiki/v0/release/yz66ojshv5htbfcysktcw3dq5e

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

4 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38588541&oldid=1839430383"